ReviewCurrent rheumatology reports2019
The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus.
Review in Current rheumatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Beyond conventional treatment: Novel cell therapies for systemic lupus erythematosus.Journal of translational autoimmunity · 2025Review
- Article
- RNA sensing at the crossroads of autoimmunity and autoinflammation.RNA (New York, N.Y.) · 2025Review
- Towards precision medicine for systemic lupus erythematosus and neuropsychiatric manifestations.Expert review of precision medicine and drug development · 2025Article
- Identifying genetic variants that influence the abundance of cell states in single-cell data.Nature genetics · 2024Article
- Identifying genetic variants that influence the abundance of cell states in single-cell data.bioRxiv : the preprint server for biology · 2023Article
- The link between post-traumatic stress disorder and systemic lupus erythematosus.Brain, behavior, and immunity · 2023Review
- The axis of complement C1 and nucleolus in antinuclear autoimmunity.Frontiers in immunology · 2023Review
- The emerging role of noncoding RNAs in systemic lupus erythematosus: new insights into the master regulators of disease pathogenesis.Therapeutic advances in chronic disease · 2023Review
- Single Nucleotide Polymorphism rs6445975 in theIranian journal of public health · 2022Article
- Genotype Triad forDiagnostics (Basel, Switzerland) · 2022Article
- Article
- Global discovery of lupus genetic risk variant allelic enhancer activity.Nature communications · 2021Article
- STAT4 Is Largely Dispensable for Systemic Lupus Erythematosus-like Autoimmune- and Foreign Antigen-Driven Antibody-Forming Cell, Germinal Center, and Follicular Th Cell Responses.ImmunoHorizons · 2021Article
- Aberrant Non-Coding RNA Expression in Patients with Systemic Lupus Erythematosus: Consequences for Immune Dysfunctions and Tissue Damage.Biomolecules · 2020Review
- Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries.American journal of human genetics · 2020Article
- Gene polymorphisms and serum levels of sVEGFR-1 in patients with systemic lupus erythematosus.Scientific reports · 2020Article
- Exploring the Role of Non-Coding RNAs in the Pathophysiology of Systemic Lupus Erythematosus.Biomolecules · 2020Review
- Genetics of rheumatic fever and rheumatic heart disease.Nature reviews. Cardiology · 2020Review
- New Frontiers: ARID3a in SLE.Cells · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewSystemic lupus erythematosus (SLE) is a complex autoimmune disease with strong genetic associations. Here, we provide an update on recent advancements in validating SLE candidate genes and risk variants identified in genome-wide association studies (GWAS). RECENT
findingsA pairing of computational biology with new and emerging techniques has significantly increased our understanding of SLE associated variants. Specifically, generation of mutations within mice and examination of patient samples has been the dominant mechanisms for variant validation. While progress has been made in validating some genes, the number of associated genes is growing with minimal exploration of the effects of individual variants on SLE. This indicates that further examination of SLE risk variants in a cell-type-specific manner is required for better understanding of their contributions to SLE disease mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.